Status:
COMPLETED
Rasburicase as a Uricolytic Therapy for Hyperuricemia in Patients With Leukemia or Lymphoma
Lead Sponsor:
Sanofi
Conditions:
Hyperuricemia
Leukemia
Eligibility:
All Genders
18-74 years
Phase:
PHASE2
Brief Summary
The primary objectives of the study are to evaluate the safety and the efficacy in patients with malignant lymphoma or acute leukemia who are repeatedly administered for SR29142 5 days in two dosage g...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Patient suffering from:
- acute leukemia with white blood cell (WBC) count≥ 20,000/mm3 without regard to uric acid level ; or
- lymphoma,Stage ≥ III without regard to uric acid level; or
- lymphomas, Stage II with bulky disease; or
- lymphoma or leukemia, without regard to classification or morphology, with uric acid level ≥ 8.0 mg/dL, and lactate dehydrogenase (LDH) level ≥ twice the upper limit of normal (ULN).
Exclusion
Key Trial Info
Start Date :
April 1 2003
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2004
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT00631579
Start Date
April 1 2003
End Date
June 1 2004
Last Update
October 2 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Sanofi-Aventis
Tokyo, Japan